SCHEMBL3416623

SCHEMBL3416623

COC(=O)c1ccc(Cl)c(-c2ccc(OC)c(CNC(=O)OC(C)(C)C)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
HIF1A Q16665 1/20 0.40
SUV39H2 Q9H5I1 2/20 0.39
PPARD Q03181 2/20 0.39
PPARG P37231 2/20 0.39
PPARA Q07869 1/20 0.39
NLRP3 Q96P20 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
USP7 Q93009 1/20 0.37
CYP1A2 P05177 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
ROCK2 O75116 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3413912 0.90 PPARD (0.42) HIF1APPARDPPARGPPARASMN1; SMN2
SCHEMBL3417468 0.89 PPARD (0.47) PPARDPPARGPPARANLRP3
SCHEMBL3417162 0.88 BDKRB1 (0.42) HIF1APPARDPPARGPPARASMN1; SMN2
SCHEMBL3414183 0.84 LMNA (0.43) KDM4EPPARDPPARGPPARASMN1; SMN2
SCHEMBL3416346 0.83 PPARG (0.53) KDM4EHIF1APPARDPPARGPPARA
SCHEMBL13433262 0.80 HDAC1 (0.48) KDM4EPPARDPPARGPPARASMN1; SMN2
SCHEMBL23088178 0.80 BDKRB1 (0.44) LMNAHTTRAB9A
SCHEMBL3413999 0.79 EGFR (0.41) KDM4EPPARDPPARGPPARALMNA
SCHEMBL3413504 0.79 PPARD (0.51) PPARDPPARGPPARANLRP3MGLL
SCHEMBL3415048 0.79 CA12 (0.44) KDM4ESMN1; SMN2MAPTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-7687664-B2 Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-30 US disclosed
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-10-28 US disclosed
EP-1394147-A1 CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME Eisai Co., Ltd. (JP) 2004-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same GPR119, NR3C1, INSR KDM4E 3724/4885HIF1A 381/4885SUV39H2 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.